Newron Declines 12% in Zurich Trading as Talks Over Sale to Santhera End
Newron Pharmaceuticals SpA, the Italian drugmaker developing a Parkinson’s disease treatment with Merck KGaA, fell in Zurich trading after saying talks with Santhera Pharmaceuticals Holding AG have ended.
The stock fell 80 centimes, or 12 percent, to 5.90 Swiss francs at 9:05 a.m.
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.